CorConsult Rx - P-glycoprotein is an efflux pump that transports some drugs and drug metabolites from circulation back to the gut, where they can be eliminated in the stool. This transporter is
![Table 2 from Natural Products as Alternative Choices for P-Glycoprotein (P- gp) Inhibition | Semantic Scholar Table 2 from Natural Products as Alternative Choices for P-Glycoprotein (P- gp) Inhibition | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/aee9588a797ef8c0d21cd66a91c055219a25a7e0/10-Table2-1.png)
Table 2 from Natural Products as Alternative Choices for P-Glycoprotein (P- gp) Inhibition | Semantic Scholar
![Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/ddi/2020/apixaban-direct-factor-xa-inhibitor-1024x576.jpg)
Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation
![Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment | Journal of Medicinal Chemistry Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b01457/asset/images/large/jm-2017-01457f_0008.jpeg)
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment | Journal of Medicinal Chemistry
![Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy](https://static.hindawi.com/articles/bmri/volume-2015/484963/figures/484963.fig.001b.jpg)
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy
![Frontiers | Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics Frontiers | Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics](https://www.frontiersin.org/files/Articles/561936/fonc-10-561936-HTML-r1/image_m/fonc-10-561936-t002.jpg)
Frontiers | Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
![Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy](https://static.hindawi.com/articles/bmri/volume-2015/484963/figures/484963.fig.002.jpg)
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy
![Table 1.4 from P-glycoprotein inhibition as a strategy to increase drug delivery across the blood-brain barrier: focus on antidepressants | Semantic Scholar Table 1.4 from P-glycoprotein inhibition as a strategy to increase drug delivery across the blood-brain barrier: focus on antidepressants | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cb07bdccd7c7e764d8e619d6a15ecce23b7d8307/49-Table1.4-1.png)
Table 1.4 from P-glycoprotein inhibition as a strategy to increase drug delivery across the blood-brain barrier: focus on antidepressants | Semantic Scholar
![ASCP10-Don't use strong CYP3A4 and P-glycoprotein inhibitors or inducers with Direct Oral Anticoagulants (DOACs) and periodically assess the medication regimen for such drug-drug interactions. | Choosing Wisely ASCP10-Don't use strong CYP3A4 and P-glycoprotein inhibitors or inducers with Direct Oral Anticoagulants (DOACs) and periodically assess the medication regimen for such drug-drug interactions. | Choosing Wisely](https://www.choosingwisely.org/wp-content/uploads/2021/05/ASCP-CLR-logo-NoTag-RGB-01smaller.png)
ASCP10-Don't use strong CYP3A4 and P-glycoprotein inhibitors or inducers with Direct Oral Anticoagulants (DOACs) and periodically assess the medication regimen for such drug-drug interactions. | Choosing Wisely
![SciELO - Brasil - Overview of P-glycoprotein inhibitors: a rational outlook Overview of P-glycoprotein inhibitors: a rational outlook SciELO - Brasil - Overview of P-glycoprotein inhibitors: a rational outlook Overview of P-glycoprotein inhibitors: a rational outlook](https://minio.scielo.br/documentstore/2175-9790/TjKWXnrBxMvtPZWgNMDFxMM/b6b81950a2e296abac549644d5c6848b44165ac2.jpg)